

Common Antimicrobial Coverage of DxWound Organisms Bibliography

1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2014; 59(2): e10-52.
2. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. 2012; 54(12): e132-73.
3. Lashinsky JN, et al. Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant *A. baumannii*: A Review. *Infect Dis Ther*. 2017;6(2):199-211.
4. Mpenge MA and MacGowan AP. Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. *Ther Clin Risk Manag*. 2015;11:565-79.
5. Zasowski EJ, Rybak JM, Rybak MJ. The β -Lactams Strike Back: Ceftazidime-Avibactam. *Pharmacotherapy*. 2015;35(8):755-70.
6. Gible AM, Gross AE, Huang AM. Examining the Clinical Effectiveness of Non-Carbapenem β -Lactams for the Treatment of Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae. *Antibiotics*. 2015;4(4):653-66.
7. Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. *Clin Microbiol Rev*. 2013;26(3):526-46.
8. Lee CS, Doi Y. Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens. *Infect Chemother*. 2014;46(3):149-64.
9. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. *Clin Microbiol Rev*. 2014;27(4):870-926.
10. Kristich CJ, Rice LB, Arias CA. Enterococcal Infection – Treatment and Antibiotic Resistance. In: Gilmore MS, Clewell DB, Ike Y, and Shankar N, eds. *Enterococci: From Commensals to Leading Causes of Drug Resistant Infection*. Boston, MA: Massachusetts Eye and Ear Infirmary; 2014:123-184.
11. Pappas PG, Kauffman CA, Andes DR et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America, *Clin Infect Dis* 2016;62:e1–e50.
12. Patterson TE, Thompson GR, Denning DW et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;63:e1–e60.
13. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007; 175:367-416.
14. Whaley, SG, Berkow EL, Rybak JM, et al. Azole Antifungal Resistance in *Candida albicans* and Emerging Non-*albicans* *Candida* species. *Front Microbiol*. 2017;7:2173.
15. McMullen AR, Anderson N, Wallace MA, et al. When Good Bugs Go Bad: Epidemiology and Antimicrobial Resistance Profiles of *Corynebacterium striatum*, an Emerging Multidrug-Resistant, Opportunistic Pathogen. *Antimicrob Agents Chemother*. 2017;61(11).
16. Cipro® [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2016.
17. Maxipime™ [package insert]. Lake Forest, IL: Hospira, Inc; 2012.
18. Rennie RP, Jones RN. Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012. *Can J Infect Dis Med Microbiol*. 2014;25(5):285-287.
19. Morrill HJ, Pogue JM, Kaye KS, et al. Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. *Open Forum Infect Dis*. 2015;2(2):ofv050.
20. Brook I. Spectrum and treatment of anaerobic infections. *J Infect Chemother*. 2016;22(1):1-13.
21. Soderquist B, Bjorklund S, Hellmark B, et al. *Finegoldia magna* Isolated from Orthopedic Joint Implant-Associated Infections. *J Clin Microbiol*. 2017;55(11):3283-3291.
22. Murphy EC, Frick IM. Gram-positive anaerobic cocci--commensals and opportunistic pathogens. *FEMS Microbiol Rev*. 2013;37(4):520-553.



Contact CogenDx to learn more.

Client Services: (877) 866-0603

cogendx.com